- Home
- DTF vs FBIO Comparison
DTF vs FBIO Comparison
Compare DTF & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTF | FBIO |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.4M | 78.3M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DTF | FBIO |
|---|---|---|
| Price | $11.51 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 14.3K | ★ 372.0K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.22 |
| Revenue Next Year | N/A | $40.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.09 | $1.62 |
| 52 Week High | $11.60 | $4.53 |
Technical Indicators
Market Signals| Indicator | DTF | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 41.46 |
| Support Level | $11.24 | $2.20 |
| Resistance Level | $11.48 | $2.49 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 25.05 | 46.55 |
Price Performance
Historical ComparisonAbout DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.